Escherichia coli integration expression system and application thereof in enzyme high-efficiency expression

Through integration site screening and promoter optimization in E. coli, combined with T7RNA polymerase regulation, an efficient integrated expression system was constructed, which solved the genetic stability and antibiotic dependence of the plasmid expression system, and achieved efficient genomic-level expression and enzyme activity.

CN118995554AActive Publication Date: 2024-11-22JIANGNAN UNIV

Patent Information

Application Number
CN202411257100.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-22
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

The existing plasmid expression system has problems such as poor genetic stability, high antibiotic dependence and large growth burden, and there are challenges in integrating the expression system in terms of insufficient expression.

Method used

Through integration site screening, optimization of target gene promoter and modification of T7RNA polymerase regulatory originals, an efficient integrated expression E. coli system was constructed, and the genomic level was achieved by combining the Plpp-T7 promoter and the slmA site. Efficiently integrate expression and gene editing through CRISPR-Cas9 technology.

Benefits of technology

Efficient recombinant expression without antibiotic dependence was achieved, the integrated expression of reporter gene reached 1.98 times the plasmid level, and the enzyme activity and expression level reached the level comparable to that of plasmid, which significantly improved genetic stability and expression efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995554A_ABST
    Figure CN118995554A_ABST
Patent Text Reader

Abstract

The invention discloses an escherichia coli integration expression system and application thereof in enzyme high-efficiency expression. The invention systematically optimizes the integrated expression system of Escherichia coli from three aspects. The method comprises the following steps: firstly, screening an integration site slmA with the highest expression activity from 18 sites in an ORI region of an escherichia coli genome; secondly, 16 endogenous promoters in escherichia coli are identified and combined with a T7 promoter to construct multiple promoters; subsequently, the expression of the T7RNA polymerase has been optimized at the chassis cell level. Compared with a plasmid type recombinant expression mode, the obtained constitutive efficient integration expression system has the advantage that the GFP expression quantity is increased by about 2 times. Finally, the method is applied to integrated expression of nitrilase and hyaluronidase, stable and efficient enzyme expression is achieved, and the enzyme activity is equivalent to the plasmid level. In a word, the invention provides a stable and efficient gene expression method, antibiotics and inducers are not needed, and the method becomes a powerful tool for synthetic biology, enzyme engineering and related applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an Escherichia coli integrated expression system and application thereof in efficient enzyme expression, belonging to the technical field of synthetic biology. Background Art

[0002] Due to the urgent need for green manufacturing and biomanufacturing, bioengineering has received more and more attention. Many technologies such as genetic engineering, protein engineering and synthetic biology have flourished and gradually matured. Microorganisms play an important role as hosts for gene expression and regulation. In these fields, due to the convenience of plasmid experimental operation and the advantages of high yield, people usually use plasmids as vectors to express genes or pathways. However, there are two major disadvantages of plasmid expression systems. First, as non-genomic DNA, plasmids usually show poor genetic stability (plasmid loss), resulting in a decrease in the yield of recombinant bacteria or difficulty in increasing it in the later stage of fermentation. In addition, the maintenance of plasmids in host cells often requires the addition of antibiotics. However, the abuse of antibiotics and the introduction of antibiotics into the environment are likely to lead to the emergence of antibiotic-resistant bacteria and even the evolution of super bacteria. This is also considered one of the biggest health problems in the world today. Moreover, on an industrial scale, the large-scale use of antibiotics will undoubtedly increase costs.

[0003] Integrating exogenous genes into the host chromosome for expression can well avoid several disadvantages of plasmid expression. First, genes inserted into the genome can be expressed continuously and stably without any resistance screening. In addition, after the gene is integrated and expressed in the host, it is not necessary to add maintenance plasmids to replicate in the cell, thus significantly reducing the growth and metabolic pressure of the host cells. Moreover, with the rapid development of gene editing technology, more and more gene editing technologies have been developed, such as CRISPR-Cas9, CRISPR-Cpf1, and Transposon-Associated CRISPR-Cas System. These provide diversified and convenient technical strategies for integrated expression. Compared with plasmid free expression, integrated expression shows many advantages, but there is still an obvious disadvantage of insufficient expression. Many scholars integrate the genome through multiple copies and increase the gene dosage to increase the expression. For example, Zhang et al. integrated two copies of the NAD kinase gene into the genome of Escherichia coli to increase the production of poly-3-hydroxybutyrate (Zhang et al. Biotechnol Lett, 2015). In addition, Watzlawick et al. inserted 5 copies of the ganA gene expression cassette into the genome of Bacillus subtilis, achieving efficient expression and stable inheritance of β-galactosidase (Watzlawick and Altenbuchner, AMB Express, 2019). However, although multi-copy number integration can significantly increase the expression of genes at the genome level, the experimental process is cumbersome, and the multi-copy number gene expression cassette in the genome will bring significant growth burden to the host. Summary of the invention

[0004] To solve the above problems, the present invention provides an Escherichia coli system that can achieve efficient integration expression through screening of integration sites, optimization of target gene promoters and modification of T7 RNA polymerase regulatory elements, and uses target genes encoding different enzymes for verification to determine the feasibility of the system for efficient expression of exogenous genes.

[0005] The first object of the present invention is to provide a recombinant Escherichia coli for efficiently integrating and expressing a target gene, wherein the recombinant Escherichia coli comprises the following modifications: integrating a target gene expression cassette into the slmA site of the Escherichia coli host genome, and replacing the regulatory element of the T7 RNA polymerase encoding gene on the genome;

[0006] The target gene expression frame contains the target gene and a first promoter that starts the expression of the target gene, wherein the first promoter is a tandem promoter, and the tandem promoter is obtained by connecting one or more of the Plpp promoter, the PgapA promoter, and the PssrA promoter in series with the T7 promoter.

[0007] The regulatory element includes a lactose operon located upstream of a T7 RNA polymerase encoding gene, and the regulatory element is replaced by an element containing a second promoter, wherein the second promoter is selected from a PalsR promoter or a PasnB promoter.

[0008] Since plasmid-mediated microbial fermentation has the disadvantages of additional growth burden, genetic instability and antibiotic contamination, it is very important to enhance the expression of exogenous genes at the genome level. Therefore, the purpose of the present invention is to construct an efficient integration expression system with a single copy number at the genome level to achieve efficient recombinant expression of genetic stability that is not dependent on antibiotics. Escherichia coli is favored by researchers because of its convenient genetic manipulation and strong expression ability. Therefore, in the present invention, we use Escherichia coli BL21 (DE3) as a model strain. In order to further reduce the cost of recombinant expression, we are committed to constructing a constitutive efficient integration expression system to avoid the cost of IPIG addition. Many scholars have shown in previous studies that genes at different positions on chromosomes will show significant differences in their expression levels. Bryant proved in his study that in the same expression cassette, green fluorescent protein can show a 300-fold expression difference on the Escherichia coli genome (Bryant et al. Nucleic Acids Res, 2014). Therefore, in our study, we selected 18 integration sites in the ORI structured macrodomain region of the Escherichia coli chromosome, and through the characterization of the expression intensity of these 18 integration sites, we discovered a site with the highest expression activity, slmA. On this basis, in order to further improve the integration expression, we designed the promoter elements in the expression cassette. We first characterized 16 constitutive promoters of Escherichia coli. Then, these 16 promoters were combined with the T7 promoter to construct 16 dual promoters and 10 triple promoters. In this series of promoter libraries, a high-intensity promoter Plpp-T7 was discovered, and its expression intensity was 3.3 times that of the T7 promoter under constitutive expression. Afterwards, we combined the high-intensity Plpp-T7 promoter with the high-expression active site slmA, and the integration expression amount was able to reach 74% of the expression amount of plasmid pET-3b. In order to achieve a higher intensity of constitutive integration expression, we further constitutively regulated the T7 RNA polymerase (lactose operon leaky expression) in the Escherichia coli BL21 (DE3) genome. The integration expression of EGFP was successfully achieved to 1.98 times of the plasmid level. Thus, a constitutive and efficient integration expression system was constructed. Finally, we also used the constructed system to integrate nitrilase and hyaluronidase. The enzyme activity and expression level of the obtained integrated strain were able to reach the same level as the plasmid.

[0009] Furthermore, in the tandem promoter, the Plpp promoter, the PgapA promoter or the PssrA promoter is located before the T7 promoter.

[0010] Preferably, the tandem promoter comprises Plpp promoter, PgapA promoter, PssrA promoter, Plpp-T7 promoter, PgapA-T7 promoter, PssrA-T7 promoter, PgapA-Plpp-T7 promoter, PgapA-PssrA-T7 promoter, Plpp-PgapA-T7 promoter, Plpp-PssrA-T7 promoter, PssrA-PgapA-T7 promoter or PssrA-Plpp-T7 promoter. In each tandem promoter of the embodiment of the present invention, the promoters are directly connected.

[0011] Furthermore, the target gene expression frame and / or the element containing the second promoter also contains RBS; the sequence of the RBS is shown in SEQ ID NO.12.

[0012] Furthermore, the slmA site is shown in SEQ ID NO.1.

[0013] Furthermore, integration is performed through CRISPR-Cas9 technology, and the editing elements required for integration into the slmA site include sgRNA; the sequence of the sgRNA is shown in SEQ ID NO.2.

[0014] Furthermore, the sequences of the Plpp promoter, PgapA promoter, and PssrA promoter are shown in SEQ ID NO.3-5, respectively, and the sequence of the T7 promoter is shown in SEQ ID NO.6.

[0015] Furthermore, the sequence of the regulatory element is shown in SEQ ID NO.7.

[0016] Furthermore, the sequences of the PalsR promoter and the PasnB promoter are shown in SEQ ID NOs.8-9, respectively.

[0017] Furthermore, the Escherichia coli host includes Escherichia coli BL21 (DE3).

[0018] The second object of the present invention is to provide a constitutive dual promoter with high expression intensity, wherein the constitutive dual promoter is obtained by directly connecting the Plpp promoter to the front of the T7 promoter.

[0019] The third object of the present invention is to provide the use of the above-mentioned recombinant Escherichia coli or constitutive dual promoter in the integration and expression of target genes.

[0020] Furthermore, the target gene is a gene encoding an exogenous protein (enzyme), including but not limited to nitrilase, hyaluronidase, etc.

[0021] Furthermore, the sequence of the nitrilase is shown as SEQ ID NO.10; the sequence of the hyaluronidase is shown as SEQ ID NO.11.

[0022] The fourth object of the present invention is to provide a method for efficiently integrating and expressing a target gene, comprising the step of fermenting with the recombinant Escherichia coli.

[0023] Specifically, the present invention provides an Escherichia coli efficient integrated expression system CEIES_Ecoli, which combines the Plpp-T7 promoter, the genomic integration site slmA and the high integration expression intensity Escherichia coli chassis cell BslG-alsR to construct an integrated expression system to achieve efficient constitutive integrated expression of Escherichia coli.

[0024] Preferably, the Escherichia coli efficient integrated expression system CEIES_Ecoli is used to achieve integrated expression of the nitrilase from Pseudomonasputida CGMCC3830, and the enzyme activity can reach 22.87U·mL -1 .

[0025] Preferably, the Escherichia coli efficient integrated expression system CEIES_Ecoli is used to achieve the integrated expression of hyaluronidase from Citrobacterfreundii, and the enzyme activity can reach 12195U·mL -1 .

[0026] Beneficial effects of the present invention:

[0027] (1) The present invention uses Escherichia coli as a model strain, and constructs a highly efficient integrated expression system with a single copy number at the genome level through the screening and optimization of the original components, achieving highly efficient recombinant expression of genetic stability that is not dependent on antibiotics, and successfully making the integrated expression amount of the reporter gene reach 1.98 times and 2.07 times that of the plasmid level. At the same time, the constructed system is used to integrate and express nitrilase and hyaluronidase, and the enzyme activity and expression amount of the obtained integrated strain can reach a level comparable to that of the plasmid.

[0028] (2) The highly efficient integrated expression system constructed in the present invention can achieve efficient protein recombinant expression without the addition of antibiotics or inducers, and has significantly superior genetic stability. While reducing fermentation costs, it fundamentally avoids antibiotic residues, antibiotic abuse and pollution problems. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1To screen for integration sites with high expression activity in the Escherichia coli genome.

[0030] Figure 2 For the characterization and combinatorial construction of constitutive promoters.

[0031] Figure 3 Construction of an E. coli integrative expression system.

[0032] Figure 4 Enzyme activity curves of recombinant nitrilase and hyaluronidase in Escherichia coli. DETAILED DESCRIPTION

[0033] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0034] The method of the present invention is as follows:

[0035] Selection of genomic integration sites

[0036] In the present invention, 18 genome integration sites for integration expression were selected in the ORI region of the Escherichia coli BL21 (DE3) genome. In order not to destroy the original metabolic pathway and gene expression of Escherichia coli, these 18 integration sites were selected between the genes of the genome. The integration sites are named after the nearby genes.

[0037] Construction of sgRNA expression plasmid pTargetF

[0038] Plasmid pTargetF was used as a template for inverse PCR. The N20 sequence of sgRNA was introduced into pTargetF by inverse PCR reaction. The PCR program was set as follows: 95°C for 3 min, 95°C for 30 s, 60°C for 30 s, 72°C for 5 min, 35 cycles, and a final extension time of 10 min. After digesting the PCR product with endonuclease DpnI at 37°C for 2 hours, the mixture was transformed into Escherichia coli JM109, and positive mutants were confirmed by sequencing.

[0039] E. coli gene editing

[0040] The pCas plasmid was transformed into E. coli BL21(DE3) competent cells to obtain BL21(DE3)-pCas. The homology arms were fused to the integration fragment by overlap extension-PCR to construct donor DNA. The constructed pTargetF plasmid and donor DNA were simultaneously transformed into E. coli BL21(DE3)-pCas competent cells. Single colonies were selected for colony PCR and DNA sequencing verification.

[0041] Construction of recombinant plasmids of green fluorescent protein, nitrilase and hyaluronidase

[0042] In the present invention, pET-3b is used as an expression vector. The green fluorescent protein gene gfp (GenBank: AAB02572.1) was codon optimized in Escherichia coli. In addition, the present invention also performed codon optimization on the genes of nitrilase (derived from Pseudomonas putida CGMCC3830) and hyaluronidase (derived from Citrobacter freundii). Then, the gfp gene was connected between NdeI and BamHI of the plasmid pET-3b by homologous recombination. The ligation product was transformed into Escherichia coli JM109 competent cells. Finally, the cells were collected by centrifugation and coated on agar LB medium containing ampicillin. After culturing for 12 hours, a single colony was selected for PCR and DNA sequencing. The recombinant plasmids of nitrilase and hyaluronidase were constructed in the same way.

[0043] Construction of promoter engineering plasmid

[0044] The pET3b-GFP plasmid was digested with SalI and XbaI restriction enzymes, and an endogenous promoter of E. coli was inserted into the position to construct a single promoter plasmid (replacing the T7 promoter). The pET3b-GFP plasmid was digested with SalI and BglII restriction enzymes, and an endogenous promoter of E. coli was inserted into the position to construct a dual promoter plasmid (inserting upstream of the T7 promoter). First, two endogenous promoters were fused and amplified by extended PCR, and then the SalI and BglII restriction sites of the pET3b-GFP plasmid were inserted to construct a triple promoter plasmid.

[0045] Recombinant Expression of Nitrilase and Hyaluronidase in Escherichia coli

[0046] Recombinant E. coli, including integrated and plasmid expression strains, were cultured in 10 mL LB at 37°C and 220 rpm for 10-14 h. They were then transferred to 30 mL LB at 1% inoculum and cultured for 8 h to express nitrilase and hyaluronidase. After collecting cells from the fermentation broth, the recombinant E. coli cells were lysed and the cell lysate supernatant was mixed with SDS loading buffer. The samples were boiled for 15 min and then used for SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) analysis.

[0047] Hyaluronidase enzyme activity detection method

[0048] In the present invention, the reaction system consists of 100 μL reaction buffer, 50 μL 2 g·L -1The hyaluronic acid solution and 50 μL bacterial culture supernatant were reacted at 37°C for 1 hour, and then 40 μL of 0.8M K2B4O7 solution was added, and the mixture was placed in a boiling water bath for 3 minutes and cooled in an ice bath. Then, 1.2 mL of DMAB solution diluted with glacial acetic acid was added and incubated at 37°C for 20 minutes. The reaction solution after incubation was transferred to a 96-well cell culture plate, the absorbance was measured at 585 nm, and the enzyme activity was calculated by substituting it into the acetylglucosamine standard curve. One enzyme activity unit (1U) is defined as the amount of enzyme required to catalyze the generation of 1 nmol acetylglucosamine equivalents in one minute at 37°C.

[0049] Nitrilase enzyme activity detection method

[0050] The biocatalytic reaction in the nitrilase activity assay in this study adopted the whole-cell catalytic method, with nitrilase recombinant Escherichia coli cells as biocatalysts and Escherichia coli BL21 (DE3)-pET3b cells as blank controls. The method for determining the nitrilase activity was to mix the substrate solution (3-cyanopyridine final concentration of 50 mM) and nitrilase in PBS (100 mM, pH 7.2). Take 1 mL of the mixture, pre-incubate in a constant temperature oscillator for 5 minutes, and then incubate at 30°C and 1500 rpm for 10 minutes. Centrifuge the mixture at 12,000g for 1 minute to terminate the enzymatic reaction. The enzyme activity was determined by measuring the amount of ammonia produced in the reaction mixture using the phenol-hypochlorite method 30. The above-mentioned substrate solution, PBS and phenol-hypochlorite solution all used boiled water to eliminate ammonia in the water. One unit (1U) of enzyme activity is defined as the amount of enzyme that produces 1 μmol of ammonia per minute under the above-mentioned standard conditions.

[0051] The sequence involved in the present invention is as follows:

[0052] Integration site slmA, the underlined part is replaced during the gene editing process of integrating the target fragment into the genome (SEQ ID NO.1)

[0053] tgaaggtatgctgtcacgttttgtccgcagcgaatttaaataccgcccgacggatgattttgacgcccgctggccgctaattgccgcgcagttgcagtaa tatgacgccggatgacttttcatccggcgagtttct The sgRNA gene sequence of ttaaacgccaaactcttcgcgataggccttaaccgccgccagatgttccgccatttccggcttctcttccagataggcaatcagatctttcagggtgatgslmA (SEQ ID NO. 2)

[0054] acgccggatgacttttcatcgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaa aagtggcaccgagtcggtgc

[0055] Plpp(SEQ ID NO.3)

[0056] tttgtatatcgaagcgccctgatgggcgctttttttatttaatcgataaccagaagcaataaaaaatcaaatcggatttcactatataatctcactttatctaagatgaatccgatggaagcatcctgttttctctcaatttttt tatctaaaacccagcgttcgatgcttctttgagcgaacgatcaaaaataagtgccttcccatcaaaaaaatattctcaacataaaaaactttgtgtaatacttgtaacgctacatggagattaactcaatctagagggtattaata

[0057] PgapA(SEQ ID NO.4)

[0058] ttgctcacatctcactttaatcgtgctcacattacgtgactgattctaacaaaacattaacaccaactggcaaaattttgtcctaaacttgatctcgacgaaatggctgcacctaaatcgtgatgaaaatcacatttttatcgtaattgccctttaaaattcggggcgcc gacccccatgtggtctcaagcccaaaggaagagtgaggcgagtcagtcgcgtaatgcttaggcacaggattgatttgtcgcaatgattgacacgattccgcttgacgctgcgtaaggtttttgtaattttacaggcaaccttttattcactaacaaatagctggtggaatat

[0059] PssrA(SEQ ID NO.5)

[0060] ccagttcctcaccgcgcctccctctccggcggcgcgaatgaacatcttattggctatcacatccgacacaaatgttgccatcccattgcttaatcgaataaaaatcaggctacatgggtgctaaatctttaacgataacgccattgaggctggtcatggcgctcataaatctggtatacttacctttacacatt

[0061] T7 (SEQ ID NO.6)

[0062] TAATACGACTCACTATAGG

[0063] The part replaced before T7 RNA polymerase (SEQ ID NO.7)

[0064] tcgtataatgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacggattcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgctttgcctggtttccggcaccagaagcggtgccggaaagctggctggagtgcgatcttcctgaggccgatactgtcgtcgtcccctcaaactggcagatgcacggttacgatgcgcccatctacaccaacgtgacctatcccattacggtcaatccgccgtttgttcccacggagaatccgacgggttgttactcgctcacatttaatgttgatgaaagctggctacaggaaggccagacgcgaattatttttgatggcgtcgggatctgatccggatttactaactggaagaggcactaa

[0065] alsR (SEQ ID NO.8)

[0066] TCATCTTCCCCGTCCGTGCAAAACTTCACAATCAAAAAACATTTGTGATGTTAATGAATTAAAAACACCCAAAATCGATGAATTACGCCTTCCTGATCTGTTTTACAGAGTTACATCTGACAGCGCAATAGCGTTAAAGACACTCACCATCCAGCAACATCTATCATCTAAAAAACCAGAAAAACAAATAACATCATGTTTTTAAACTAATTAAATGAAATAAAATTTTAAGCCACTCGCCATTGTTCACAATAAAATAAACTTTATAAATTTTATTTTTTTGTGAAGTCGCCAGCATCTTTTCTGTTCTTGCTGTGGTGATATAGTGGCGTCTTCAATTCAAGGACAAGAGAACGTG

[0067] asnB (SEQ ID NO.9)

[0068] ATAGCAACCACGTCTGCGGACGTGGTTGGCTCTGATGACAAACGCCAAACTGCCTGATGCGCTACGCTTATCAGGCCTACGCAGCTCCTGCAATATATTGAATTTTCATGCTTTTGTAGGCCGGATAAGGCGTTCACGCCGCATCCGGCATGAACAAATTGCACTTTGTCAGCAATTTGGCCCCCGTAAAATATAACCATTCAATAAAACCCGCTAAAAATTATCGATTCATCAATAAATACATCCTTACACCAGACCTTTTTTCACCAATCGACAATCACCATTACGTTTTTTATTTTTTCACCGCCAAATCGCTTGCGCACAGTGCTGCTTTGCGGCATTTTTTTAAACAAGCAAACACAACAAGCAACAAATACCAGGTTAACGGAGAAGGTT Nitrilase (SEQ ID NO.10)

[0069]

[0070] Hyaluronidase (SEQ ID NO.11)

[0071]

[0072] RBS (SEQ ID NO.12)

[0073] TTTGTTTAACTTTAAGAAGGAGA

[0074] Example 1: Exploration of high expression activity integration sites in the Escherichia coli genome

[0075] The phenomenon of "position effect" has a significant impact on chromosomes in cell systems, that is, the expression intensity of genes in the genome is regulated according to the specific position of these genes on the chromosome. The Escherichia coli chromosome is divided into four structured macrodomains (Ori, Right, Ter, and Left) and two unstructured macrodomains (NSL and NSR) ( Figure 1 .A). We focused on the vicinity of the Ori macrostructure region. Based on the survey, we selected 18 integration sites on the genome of E. coli BL21 (DE3). In addition, most of the selected integration sites were located between genes, aiming to preserve the original gene expression and metabolic pathways of the strain without causing damage. The green fluorescent protein gene (gfp) was expressed as a reporter gene in the form of a constitutive T7 expression cassette, and the expression cassette was inserted into the selected 18 sites using CRISPR-Cas9 genome editing technology ( Figure 1 .A). After constructing 18 Escherichia coli strains with integrated green fluorescent protein (GFP), their growth was tested. The results showed that the genomic insertion of the reporter gene expression cassette had no significant effect on cell growth ( Figure 1 .B). Subsequently, these integrated strains were cultured to express GFP, and the fluorescence intensity of GFP was detected to characterize the expression level of E. coli integrated at different sites. The results showed that there were significant differences in the expression of E. coli with GFP gene integrated at 18 different integration sites ( Figure 1 .C), and the expression level of the strain with reporter genes integrated at the four sites closest to OriC (glmS, xylA, aslA and slmA) happened to be relatively high. Among them, the expression level difference between the strain with the highest expression level (B-slmA) and the strain with the lowest expression level (B-melB) was 2.13 times ( Figure 1 .C). In addition, among the remaining 17 integration sites, slmA had the highest relative mRNA transcription level, which was 1.85 times that of melB, the site with the lowest relative mRNA level ( Figure 1 .D). Therefore, the present invention selects slmA as a high expression active site for subsequent integration expression. Although the integration expression intensity of B-slmA shows a clear advantage among the 18 strains, the expression amount of the plasmid strain is about 1.75 times that of B-slmA, and further research is still needed to obtain an efficient integration expression system.

[0076] Example 2: Characterization of endogenous constitutive promoters in E. coli

[0077] The promoter is a DNA sequence located 5' upstream of the structural gene, which plays a vital role in the specific recognition and binding of RNA polymerase. At the transcriptional level, the promoter determines the start time and intensity of structural gene expression. The present invention selected 16 promoters from key pathways such as the tricarboxylic acid cycle, glycolysis, RNA transcription and molecular chaperones, and characterized the constitutive expression intensity of these 16 promoters. We replaced the T7 promoter of pET-3b with these 16 promoters, inserted the gfp gene into the expression cassette, and constructed 16 recombinant plasmid strains of Escherichia coli on this basis. The fluorescence intensity results showed that there were significant differences in the expression levels of these 16 promoters ( Figure 2 .A). Overall, this group of promoters can be roughly divided into four categories according to their expression strength, namely weak (PsucA, PaceE and PmglB), low level (Pmdh, Ppgi, PldhA and PasnB), medium level (PalsR, Picd, PrpoH, Pfnr, PgrpE and PdnaKJ) and high level (Plpp, PgapA and PssrA). In the case of constitutive expression, the strength of high-level promoters is significantly higher than that of T7 promoter, which are 1.74, 1.75 and 2.57 times that of T7 promoter, respectively. It can be observed that multiple potential promoter expression elements can be obtained through endogenous promoter screening. Among them, the promoter with the lowest expression level (PsucA) to the promoter with the highest expression level (PssrA) spans a range of 178 times.

[0078] Example 3: Characterization of endogenous-T7 promoter combination strength

[0079] Through the identification of endogenous promoters, 16 constitutive promoters of E. coli were obtained. Under constitutive expression, the expression strength of 4 promoters exceeded that of T7 promoter. In order to obtain a stronger promoter, we adopted the strategy of endogenous-T7 promoter combination and inserted these 16 endogenous promoters into the upstream of T7 promoter of plasmid pET3b-GFP ( Figure 2.B), and on this basis, 16 dual-promoter GFP expression strains were constructed. The results of fluorescence detection showed that, except for PssrA-T7, the expression levels of the combined dual promoters were significantly higher than those of the endogenous promoters. Further analysis found that the dual promoters combined with high-level promoters (Plpp, PgapA and PssrA) did not show the significant enhancement effect shown by the other 13 promoters when combined with the T7 promoter. Despite this, the three dual promoters, Plpp-T7, PgapA-T7 and PssrA-T7, exerted their inherent expression advantages as single promoters, and their expression levels were still significantly better than the other 13 dual promoters ( Figure 1 .A, B). It is worth noting that the expression level of Plpp-T7 is 1.89 times that of Plpp and 3.30 times that of T7 promoter ( Figure 2 .B).

[0080] After obtaining a dual promoter with high expression intensity, we constructed 10 endogenous-endogenous-T7 combinations of triple promoters to obtain a combination promoter with higher expression intensity. However, these results showed that the expression levels of the 10 triple promoters were lower than that of the Plpp-T7 dual promoter ( Figure 3 .C). It can be seen that the expression of Plpp-T7 shows obvious advantages among single, double and triple promoters. Therefore, the present invention selects Plpp-T7 promoter as the final promoter in the integrated expression cassette.

[0081] Example 4: Plpp-T7 promoter enhances integration expression strength

[0082] In the above study, we obtained a high expression integration site slmA and a high expression dual promoter Plpp-T7. We speculated that combining these two aspects might further enhance integration expression. Therefore, we inserted the gfp expression cassette of the Plpp-T7 promoter into the slmA site of the E. coli BL21(DE3) genome ( Figure 1 .A), the strain B-slmA-PlppT7-GFP (BslG) was constructed. The results showed that the expression level of GFP in BslG was increased to 1.30 times compared with the strain with T7 expression cassette inserted (B-slmA) ( Figure 3 .A, B), in addition, the expression of gfp gene also showed a significant increase at the transcriptional level ( Figure 3 .C). This indicates that the dual promoter Plpp-T7 constructed by the above study combined with the promoter strategy can still show an enhanced effect at the genome level. However, despite the use of the high-intensity combined promoter Plpp-T7 and the high expression activity integration site slmA, the expression level of the plasmid expression strain Escherichia coli BL21 (DE3)-pET3b-GFP was still 1.35 times higher than that of BslG ( Figure 3 .B, C), so the next step of the study will be to further enhance the expression of BslG by transforming chassis cells.

[0083] Example 5: Chassis cell modification to enhance E. coli integration expression capability

[0084] In the above study, the integrated expression cassette we constructed contained a T7 promoter, which could be specifically recognized and transcribed by T7 RNA polymerase, while the original T7 RNAp expression system of E. coli BL21 (DE3) was leaked by the PlacUV5 promoter under the control of the lactose operon ( Figure 3 .D), in the case of constitutive expression, due to the absence of induction by lactose analogs, only a small amount of T7 RNAp participates in the transcription process of the T7 promoter. Therefore, we speculate that the expression efficiency of the T7 promoter can be improved by increasing the expression of T7 RNAp in E. coli cells.

[0085] The present invention aims to develop an efficient, induction-free integrated expression system, thereby avoiding the cost of adding IPTG and enabling constitutive expression of T7RNAp. Therefore, we selected 6 promoters of different strengths ( Figure 2 .A), low level (Ppgi and PasnB), medium level (PalsR and PrpoH) and high level (PgapA and PssrA). At the BslG genome level, these six promoters were used to edit and replace a series of expression elements upstream of the T7RNAp gene ( Figure 3 .D, where the replaced sequence is shown in SEQ ID NO.7, and the replaced elements include the promoter and RBS elements), and six T7RNAp expression regulation strains were constructed. Then, the expression of GFP in these six strains was determined. The above results showed that the expression levels of BslG-alsR and BslG-asnB were 2.72 times and 2.83 times that of BslG, respectively ( Figure 3 E). More importantly, the expression levels of BslG-alsR and BslG-asnB were 1.98 and 2.07 times higher than those of the plasmid expression strain E. coli BL21(DE3)-pET3b-GFP, respectively. In the above study, efficient integration expression strains BslG-alsR and BslG-asnB were obtained. Although the expression level of BslG-asnB was slightly higher than that of BslG-alsR ( Figure 3 E), but considering the significant growth advantage of BslG-alsR cells ( Figure 3 F), and believed that BslG-alsR was more suitable as a chassis cell for integration expression. Then, through the analysis of gfp gene transcription level, it was found that the relative mRNA level of BslG-alsR was increased to 1.75 times that of BslG ( Figure 3.C). This indicates that by regulating the expression of T7RNAp, the mRNA content of the target gene is increased at the transcriptional level, thereby improving the expression level. In summary, BslG-alsR was finally selected as the strain for constructing a constitutive and efficient integrated expression system (CEIES_Ecoli).

[0086] Example 6: Study on the integrated expression of nitrilase and hyaluronidase using CEIES_coli

[0087] Nitrilase can catalyze the hydrolysis of nitrile compounds into carboxylic acids and is widely used in many fields such as food, medicine, and chemical industry. In order to explore the application potential of CEIES_Ecoli developed in this study, the gfp gene in the genome of Escherichia coli BslG-alsR was replaced with the nitrilase gene in Pseudomonas putida CGMCC3830 (the strain is recorded in patent CN201110116234.9), and the integrated expression strain BslG-alsR-Nit was constructed. For comparison, we also constructed the plasmid expression strain BL21(DE3)-pET3b-Nit. SDS-PAGE results showed that the expression level of the integrated expression strain BslG-alsR-Nit could reach a level comparable to that of the plasmid expression strain BL21(DE3)-pET3b-Nit, and the enzyme activity of BslG-alsR-Nit (22.87U·mL -1 ) can reach BL21(DE3)-pET3b-Nit(20.81U·mL -1 ) is 1.1 times ( Figure 4 A, B), and the protein expression level and enzyme activity of the CEIES_Ecoli system can reach a level comparable to that of the recombinantly expressed Escherichia coli nitrilase reported in the literature.

[0088] Hyaluronidase is a glycosaminoglycan degrading enzyme that can specifically degrade hyaluronic acid and has high application value in the fields of medicine and medical cosmetology. Similarly, we used the developed CEIES_Ecoli to integrate and express the hyaluronidase from Citrobacter freundii in Escherichia coli. The results showed that the enzyme activity of the hyaluronidase integrated expression strain BslG-alsR-HylC was 1.16 times higher than that of the plasmid-based expression strain BL21(DE3)-pET3b-HylC, reaching 12195U·mL -1( Figure 4 .C, D).

[0089] Therefore, the above case studies of integrated expression of nitrilase and hyaluronidase showed that the recombinant strain constructed using CEIES_Ecoli can achieve stable and efficient expression without the addition of any antibiotics and inducers.

[0090] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A recombinant Escherichia coli for integrating and expressing a target gene, characterized in that: The recombinant E. coli comprises the following transformations: integrating the target gene expression cassette into the slmA site of the E. coli host genome, and replacing the regulatory element of the T7 RNA polymerase encoding gene on the genome; The target gene expression frame contains the target gene and a first promoter that starts the expression of the target gene, wherein the first promoter is a tandem promoter, and the tandem promoter is obtained by connecting one or more of the Plpp promoter, the PgapA promoter, and the PssrA promoter in series with the T7 promoter. The regulatory element includes a lactose operon located upstream of a T7 RNA polymerase encoding gene, and the regulatory element is replaced by an element containing a second promoter, wherein the second promoter is selected from a PalsR promoter or a PasnB promoter.

2. The recombinant Escherichia coli according to claim 1, characterized in that In the tandem promoter, the Plpp promoter, the PgapA promoter or the PssrA promoter is located before the T7 promoter; the tandem promoter includes the Plpp promoter, the PgapA promoter, the PssrA promoter, the Plpp-T7 promoter, the PgapA-T7 promoter, the PssrA-T7 promoter, the PgapA-Plpp-T7 promoter, the PgapA-PssrA-T7 promoter, the Plpp-PgapA-T7 promoter, the Plpp-PssrA-T7 promoter, the PssrA-PgapA-T7 promoter or the PssrA-Plpp-T7 promoter.

3. The recombinant Escherichia coli according to claim 1, characterized in that The target gene expression frame and / or the element containing the second promoter further contains RBS; the sequence of the RBS is shown in SEQ ID NO.

12.

4. The recombinant Escherichia coli according to claim 1, characterized in that Integration is performed via CRISPR; the editing elements required for integration into the slmA site include sgRNA; the sequence of the sgRNA is shown in SEQ ID NO.

2.

5. The recombinant Escherichia coli according to claim 1, characterized in that The E. coli host includes E. coli BL21 (DE3).

6. A constitutive dual promoter, characterized in that The constitutive dual promoter is obtained by connecting the Plpp promoter in front of the T7 promoter.

7. Escherichia coli containing the constitutive dual promoter according to claim 6.

8. Use of the recombinant Escherichia coli according to any one of claims 1 to 5, the constitutive dual promoter according to claim 6 or the Escherichia coli according to claim 7 in integrating and expressing a target gene.

9. The use according to claim 8, characterized in that: The target gene includes an enzyme coding gene; the enzyme includes nitrilase or hyaluronidase.

10. A method for integrating and expressing a target gene, characterized in that: The method comprises the step of using the recombinant Escherichia coli described in any one of claims 1 to 5 for expression.

Citation Information

Patent Citations

  • Pseudomonas putida and method for producing nicotinic acid or isonicotinic acid through converting Pseudomonas putida

    CN102337233A

  • Dual cistronic bacterial expression system

    CN106661588A

  • Method for improving extracellular secretion level of recombinant protein of escherichia coli

    CN111826389A

  • Recombinant engineering bacterium for efficiently expressing recombinant hGH, and construction method and application of recombinant engineering bacterium

    CN112239760A

  • Promoters for gene expression

    CN1190993A

Cited By

  • Phage compositions for Escherichia comprising CRISPR-CAS system and methods of use thereof

    CN117651764A

  • Stable and efficient escherichia coli gene editing system and application thereof

    CN119752967A